Type
. Side-effects of Isoprodian compared with WHO-MDT in rural Nepal. Leprosy review [Internet]. 1993;64(3):276-80. Available from: http://leprev.ilsl.br/pdfs/1993/v64n3/pdf/v64n3a14.pdf
Type
. Rehabilitation engineering and leprosy in Nepal: a personal view. Journal of medical engineering & technology. 1992;16(4):165-9.
Type
. Cellular immune responses to mycobacterial heat shock proteins in Nepali leprosy patients and controls. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association [Internet]. 1992;60(1):36-43. Available from: http://ila.ilsl.br/pdfs/v60n1a06.pdf
Type
. Self-administered dapsone compliance of leprosy patients in eastern Nepal. Leprosy review [Internet]. 1991;62(1):53-7. Available from: http://leprev.ilsl.br/pdfs/1991/v62n1/pdf/v62n1a08.pdf
Type
. [Research in developing countries: will leprosy vaccine be produced in Nepal?]. Nordisk medicin. 1990;105(12):338-9.
Type
. Self-administered drug compliance in Nepali leprosy patients. Tropical doctor. 1989;19(2):59-61.
Type
. Relapses after multidrug therapy for leprosy: a preliminary report of 22 cases in west Nepal. Leprosy review [Internet]. 1989;60(1):45-50. Available from: http://leprev.ilsl.br/pdfs/1989/v60n1/pdf/v60n1a07.pdf
Type
. Common diseases in Nepal. Kansas medicine : the journal of the Kansas Medical Society. 1989;90(3):80-1, 85.
Type
. What does distance matter? Leprosy control in West Nepal. Social science & medicine (1982). 1988;26(1):25-36.
Type
. The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients. Australian and New Zealand journal of medicine. 1987;17(6):568-73.